| Synthesis and pharmacological characterization of multiply substituted 2H-chromene derivatives as P2Y6 receptor antagonists YH Jung, Q Shah, SA Lewicki, A Pramanik, V Gopinatth, J Pelletier, ... Bioorganic & medicinal chemistry letters 75, 128981, 2022 | 12 | 2022 |
| Stereocontrolled access to thioisosteres of nucleoside di-and triphosphates HJ Zhang, M Ociepa, M Nassir, B Zheng, SA Lewicki, V Salmaso, ... Nature Chemistry 16 (2), 249-258, 2024 | 10 | 2024 |
| Alicyclic Ring Size Variation of 4-Phenyl-2-naphthoic Acid Derivatives as P2Y14 Receptor Antagonists Z Wen, A Pramanik, SA Lewicki, YH Jung, ZG Gao, JCR Randle, C Cronin, ... Journal of Medicinal Chemistry 66 (13), 9076-9094, 2023 | 8 | 2023 |
| Structure–Activity Relationship and Neuroprotective Activity of 1,5-Dihydro-2H-naphtho[1,2-b][1,4]diazepine-2,4(3H)-diones as P2X4 Receptor Antagonists KS Toti, R Verma, MJ McGonnigle, D Gamiotea Turro, Z Wen, SA Lewicki, ... Journal of medicinal chemistry 65 (20), 13967-13987, 2022 | 7 | 2022 |
| Machine learning-aided search for ligands of P2Y6 and other P2Y receptors AC Puhl, SA Lewicki, ZG Gao, A Pramanik, V Makarov, S Ekins, ... Purinergic Signalling, 1-11, 2024 | 4 | 2024 |
| 2-Substituted (N)-Methanocarba A3 Adenosine Receptor Agonists: In Silico, In Vitro, and In Vivo Characterization DK Tosh, M Pavan, C Cronin, E Pottie, TC Wan, E Chen, SA Lewicki, ... ACS Pharmacology & Translational Science, 2024 | 3 | 2024 |
| In vivo phenotypic validation of adenosine receptor-dependent activity of non-adenosine drugs C Xiao, O Gavrilova, N Liu, SA Lewicki, ML Reitman, KA Jacobson Purinergic Signalling 19 (3), 551-564, 2023 | 3 | 2023 |
| Structure activity relationships of 5-HT2B and 5-HT2C serotonin receptor antagonists: N6, C2 and 5′-Modified (N)-methanocarba-adenosine derivatives DK Tosh, MM Calkins, MS Ivancich, HA Bock, RG Campbell, SA Lewicki, ... European Journal of Medicinal Chemistry 259, 115691, 2023 | 2 | 2023 |
| Practical Stereocontrolled Access to Thioisosteres of Essential Signaling Molecules and Building Blocks for Life: Nucleoside Di-and Triphosphates HJ Zhang, M Ociepa, M Nassir, B Zheng, S Lewicki, V Salmaso, H Babury, ... | 1 | 2022 |
| Potent and Selective Human 5-HT2B Serotonin Receptor Antagonists: 4′-Cyano-(N)-methanocarba-adenosines by Synthetic Serendipity DK Tosh, M Pavan, AA Clark, J Lammers, S Villano, S Marri, ... Journal of Medicinal Chemistry 67 (23), 21264-21291, 2024 | | 2024 |
| Chimeras Derived from a P2Y14 Receptor Antagonist and UDP-Sugar Agonists for Potential Treatment of Inflammation Z Wen, A Pramanik, SA Lewicki, YH Jung, ZG Gao, JCR Randle, S Breton, ... ACS pharmacology & translational science 7 (10), 3255-3278, 2024 | | 2024 |
| Functionalized Congeners of 2H-Chromene P2Y6 Receptor Antagonists P Oliva, A Pramanik, YH Jung, SA Lewicki, JM Mwendwa, JH Park, ... Cells 13 (16), 1366, 2024 | | 2024 |
| 2-Substituted (N)-Methanocarba A3 Adenosine Receptor Agonists: In silico, in vitro and in vivo Characterization K Jacobson, DK Tosh, C Cronin, M Pavan, E Pottie, TC Wan, E Chen, ... Journal of Pharmacology and Experimental Therapeutics 389 (S3), 2024 | | 2024 |
| Synthesis And Pharmacological Validation Of Novel Neuroprotective Purinergic Receptor P2X4 Antagonists For The Treatment Of Ischemic Stroke R Verma, KS Toti, D Gamiotea Turro, Z Wen, S Lewicki, K Jacobson, ... Stroke 54 (Suppl_1), A41-A41, 2023 | | 2023 |
| Purinergic Signaling In Vivo Phenotypic Validation of Adenosine Receptor-Dependent Activity of Non-adenosine Drugs C Xiao, O Gavrilova, N Liu, SA Lewicki, ML Reitman, KA Jacobson | | 2022 |
| Machine learning‑aided search for ligands of P2Y AC Puhl, SA Lewicki, ZG Gao, A Pramanik, V Makarov, S Ekins, ... | | |